LT2314589T - Oksikodono hidrochlorido kompozicijų, turinčių mažiau nei 25 ppm 14-hidroksikodeinono, paruošimo procesas - Google Patents

Oksikodono hidrochlorido kompozicijų, turinčių mažiau nei 25 ppm 14-hidroksikodeinono, paruošimo procesas

Info

Publication number
LT2314589T
LT2314589T LTEP10011793.6T LT10011793T LT2314589T LT 2314589 T LT2314589 T LT 2314589T LT 10011793 T LT10011793 T LT 10011793T LT 2314589 T LT2314589 T LT 2314589T
Authority
LT
Lithuania
Prior art keywords
hydroxycodeinone
25ppm
less
oxycodone hydrochloride
hydrochloride compositions
Prior art date
Application number
LTEP10011793.6T
Other languages
English (en)
Lithuanian (lt)
Inventor
Robert Chapman
Lonn S. Rider
Qi Hong
Donald Kyle
Robert Kupper
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35124996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2314589(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of LT2314589T publication Critical patent/LT2314589T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP10011793.6T 2004-03-30 2005-03-30 Oksikodono hidrochlorido kompozicijų, turinčių mažiau nei 25 ppm 14-hidroksikodeinono, paruošimo procesas LT2314589T (lt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US55749204P 2004-03-30 2004-03-30
US60153404P 2004-08-13 2004-08-13
US62007204P 2004-10-18 2004-10-18
US64862505P 2005-01-31 2005-01-31
US65177805P 2005-02-10 2005-02-10

Publications (1)

Publication Number Publication Date
LT2314589T true LT2314589T (lt) 2023-06-12

Family

ID=35124996

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP10011788.6T LT2316837T (lt) 2004-03-30 2005-03-30 Oksikodono hidrochlorido, turinčio mažiau nei 25ppm 14-hidroksikodeinono, gamybos būdas
LTEP10011793.6T LT2314589T (lt) 2004-03-30 2005-03-30 Oksikodono hidrochlorido kompozicijų, turinčių mažiau nei 25 ppm 14-hidroksikodeinono, paruošimo procesas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP10011788.6T LT2316837T (lt) 2004-03-30 2005-03-30 Oksikodono hidrochlorido, turinčio mažiau nei 25ppm 14-hidroksikodeinono, gamybos būdas

Country Status (38)

Country Link
US (35) US7129248B2 (OSRAM)
EP (7) EP2305683B2 (OSRAM)
JP (8) JP4912294B2 (OSRAM)
KR (12) KR20180088505A (OSRAM)
CN (5) CN102127086B (OSRAM)
AP (1) AP2232A (OSRAM)
AR (1) AR049012A1 (OSRAM)
AT (2) ATE501150T1 (OSRAM)
AU (2) AU2005230826C1 (OSRAM)
BR (1) BRPI0508758B8 (OSRAM)
CA (3) CA2557845C (OSRAM)
CR (2) CR8593A (OSRAM)
CY (5) CY1111487T1 (OSRAM)
DE (2) DE202005021371U1 (OSRAM)
DK (6) DK2319846T3 (OSRAM)
EA (1) EA013208B1 (OSRAM)
EC (1) ECSP066953A (OSRAM)
ES (6) ES2938727T3 (OSRAM)
FI (1) FI7843U1 (OSRAM)
HR (5) HRP20110425T4 (OSRAM)
HU (3) HUE028233T2 (OSRAM)
IL (8) IL178038A (OSRAM)
LT (2) LT2316837T (OSRAM)
MA (1) MA28492B1 (OSRAM)
ME (4) ME02482B (OSRAM)
MX (2) MX363228B (OSRAM)
MY (3) MY143205A (OSRAM)
NO (1) NO337669B1 (OSRAM)
NZ (3) NZ549430A (OSRAM)
PE (1) PE20050880A1 (OSRAM)
PL (5) PL2426132T3 (OSRAM)
PT (5) PT2319846T (OSRAM)
RS (5) RS54941B1 (OSRAM)
SG (3) SG170736A1 (OSRAM)
SI (5) SI1730151T2 (OSRAM)
TW (3) TWI483944B (OSRAM)
WO (1) WO2005097801A1 (OSRAM)
ZA (1) ZA200607181B (OSRAM)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
ES2407143T3 (es) * 2003-08-06 2013-06-11 Grünenthal GmbH Forma de dosificación protegida contra un posible abuso
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TWI483944B (zh) 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB0421149D0 (en) * 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
RS51131B (sr) 2005-03-04 2010-10-31 Euro-Celtique S.A. Postupak smanjenja alfa, beta nezasićenih ketona u opioidnim kompozicijama
US20070082845A1 (en) * 2005-07-15 2007-04-12 The Penn State Research Foundation Ferritin as a therapeutic target in abnormal cells
EP2402346A1 (en) 2005-11-22 2012-01-04 Controlled Chemicals, Inc. Processes for reducing contaminating Michael acceptor levels in oxycodone and other compositions
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
US8871779B2 (en) * 2006-03-02 2014-10-28 Mallinckrodt Llc Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
CA2674915C (en) 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
ES2392594T3 (es) * 2006-10-17 2012-12-12 Penick Corporation Procedimiento para preparar oximorfona
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
CA2671518C (en) * 2006-12-04 2016-06-07 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
US7875719B2 (en) 2006-12-04 2011-01-25 Cox D Phillip Process for reducing impurities in oxycodone base
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
PL2125824T5 (pl) * 2007-03-23 2024-11-04 SpecGx LLC Ulepszony sposób wytwarzania oksymorfonu z oripawiny
WO2008130553A1 (en) * 2007-04-16 2008-10-30 Mallinckrodt Inc. Novel opiate reduction utilizing catalytic hydrogen transfer reaction
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
CN102105136B (zh) * 2008-03-11 2014-11-26 蒂宝制药公司 包含非-阿片类止痛剂和阿片类止痛剂的组合的胃滞留型缓释剂型
US8372432B2 (en) * 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2009135680A1 (en) 2008-05-09 2009-11-12 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
NZ592276A (en) * 2008-09-18 2012-12-21 Purdue Pharma Lp PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY(epsilon-CAPROLACTONE) AND AN OPIOID
PL2997965T3 (pl) * 2009-07-22 2019-06-28 Grünenthal GmbH Odporna na manipulacje postać dawkowania opioidów wrażliwych na utlenianie
WO2011009602A1 (en) * 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
PL399450A1 (pl) * 2009-08-31 2013-01-21 Depomed, Inc Utrzymujace sie w zoladku kompozycje farmaceutyczne do natychmiastowego i przedluzonego uwalniania acetaminofenu
WO2011041414A1 (en) 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
CN102821757B (zh) * 2010-02-03 2016-01-20 格吕伦塔尔有限公司 通过挤出机制备粉末状药物组合物
EP2377866B1 (en) 2010-03-23 2014-02-26 Siegfried AG Preparation of low impurity opiates in a continuous flow reactor
WO2011141489A1 (en) 2010-05-10 2011-11-17 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
NZ603170A (en) 2010-05-10 2015-04-24 Euro Celtique Sa Combination of active loaded granules with additional actives
KR101858797B1 (ko) 2010-05-10 2018-05-16 유로-셀티큐 에스.에이. 히드로모르폰 및 날록손을 포함하는 제약 조성물
TWI478928B (zh) 2010-06-11 2015-04-01 Rhodes Technologies 用於製備ｎ－烯丙基化合物之過渡金屬催化的製程及其用途
TWI471289B (zh) 2010-06-11 2015-02-01 Rhodes Technologies 使三級胺進行ｎ－脫烷反應之方法
PL2588481T3 (pl) 2010-07-02 2018-05-30 Johnson Matthey Public Limited Company Sposób syntezy i oczyszczania oksykodonu
US8912781B2 (en) * 2010-07-30 2014-12-16 Cirrus Logic, Inc. Integrated circuit switching power supply controller with selectable buck mode operation
ES2487244T3 (es) 2010-09-02 2014-08-20 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende un polímero aniónico
EP2611426B1 (en) 2010-09-02 2014-06-25 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US20130028972A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
ES2842453T3 (es) 2011-09-05 2021-07-14 Siegfried Ltd Kit que comprende un material de envasado y un producto farmacéutico o nutracéutico sólido contenido en el material de envasado
EP2755640B1 (en) 2011-09-16 2017-07-26 Purdue Pharma LP Tamper resistant pharmaceutical formulations
ES2583132T3 (es) 2011-09-16 2016-09-19 Purdue Pharma L.P. Formulaciones de liberación inmediata resistentes a alteración
ES2603278T3 (es) 2011-12-09 2017-02-24 Purdue Pharma Lp Formas farmacéuticas de dosificación que comprenden poli (epsilon-caprolactona) y óxido de polietileno
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
EA028224B1 (ru) 2012-03-02 2017-10-31 Роудс Фармасьютикалз Л.П. Лекарственные формы немедленного высвобождения с защитой от несанкционированного применения
JP6279547B2 (ja) 2012-04-17 2018-02-14 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法
HRP20181716T1 (hr) 2012-04-18 2018-12-28 Grünenthal GmbH Farmaceutski oblik doziranja otporan na zlonamjernu uporabu i naglo oslobađanje cjelokupne doze
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
BR112015000320B1 (pt) 2012-07-12 2023-03-07 SpecGx LLC Composições farmacêuticas dissuasivas de abuso e seu processo de preparação
SG11201407986QA (en) * 2012-07-16 2015-02-27 Rhodes Technologies Process for improved opioid synthesis
ES2647949T3 (es) * 2012-07-16 2017-12-27 Rhodes Technologies Proceso para la síntesis mejorada de opioides
WO2014022733A1 (en) * 2012-08-03 2014-02-06 Johnson Matthey Public Limited Company A method for preparing oxycodone
MX392839B (es) 2012-11-30 2025-03-24 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
PE20151301A1 (es) 2013-02-05 2015-09-16 Purdue Pharma Lp Formulaciones farmaceuticas resistentes a la manipulacion indebida
US9770710B2 (en) 2013-02-20 2017-09-26 University Of Washington Through Its Center For Commercialization Hydrogenation and disproportionation catalysis
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
WO2014191397A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
WO2015004245A1 (en) 2013-07-12 2015-01-15 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
GB201313211D0 (en) 2013-07-24 2013-09-04 Cambrex Karlskoga Ab New process
CN110172063A (zh) 2013-08-02 2019-08-27 庄信万丰股份有限公司 用于制备氢羟吗啡酮的方法
GB201313915D0 (en) * 2013-08-02 2013-09-18 Johnson Matthey Plc Process
PL3065743T3 (pl) 2013-11-07 2019-12-31 SpecGx LLC Sposób wytwarzania 6-hydroksymorfinanów bez izolowania związków pośrednich
UA116405C2 (uk) 2013-11-13 2018-03-12 Євро-Селтік С.А. Гідроморфон та налоксон для лікування болю та синдрому опіоїдної дисфункції кишечнику
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
US8846923B1 (en) 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
US9062062B1 (en) 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride
US10227354B2 (en) 2013-12-18 2019-03-12 Cody Laboratories, Inc. Conversion of oxycodone base to oxycodone hydrochloride
WO2015107471A1 (en) 2014-01-15 2015-07-23 Rhodes Technologies Process for improved oxycodone synthesis
CN106029669B (zh) 2014-01-15 2018-04-13 罗德科技公司 改进的羟二氢吗啡酮合成的方法
WO2015120201A1 (en) 2014-02-05 2015-08-13 Kashiv Pharma, Llc Abuse-resistant drug formulations with built-in overdose protection
JP6510628B2 (ja) 2014-03-26 2019-05-15 サン・ファーマ・アドバンスト・リサーチ・カンパニー・リミテッド 乱用防止即時放出性被覆リザーバ固体剤形
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
MA40332A (fr) * 2014-07-09 2021-04-28 Rhodes Tech Réduction des niveaux de cétone alpha, beta-insaturée dans des compositions de dérivés de morphinane
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
US20160052932A1 (en) * 2014-08-25 2016-02-25 Johnson Matthey Public Limited Company Processes for Making Opioids Including 14-Hydroxycodeinone and 14-hydroxymorphinone
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN105777766B (zh) * 2014-12-15 2017-11-24 北大方正集团有限公司 Delta‑7溴甲纳曲酮的制备方法
US9918979B2 (en) * 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
EA035434B1 (ru) 2015-04-24 2020-06-15 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
GB201513203D0 (en) 2015-07-27 2015-09-09 Cambrex Charles City Inc New process
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US20180104236A1 (en) 2016-09-26 2018-04-19 Euro-Celtique S. A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
EP3642207B1 (en) 2017-06-20 2022-08-31 Johnson Matthey Public Limited Company Hydrogenation process for preparing oxycodone hydrochloride from 14-hydroxycodeinone
WO2019006404A1 (en) 2017-06-30 2019-01-03 Purdue Pharma L.P. METHOD OF TREATMENT AND DOSAGE FORMS
CN110330500B (zh) * 2019-07-12 2021-11-23 宜昌人福药业有限责任公司 一种6β-羟基-7,8-二氢-吗啡衍生物的立体选择性合成方法
CN113009060B (zh) * 2021-02-24 2022-10-21 西南药业股份有限公司 高效液相色谱法测定盐酸羟考酮含量的方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US420098A (en) * 1890-01-28 Mowing-machine
US100000A (en) * 1870-02-22 Improved sun-bonnet for horses
US1485673A (en) 1924-03-04 Ministrator
US1468805A (en) 1923-09-25 Htabtin ereund
US105553A (en) 1870-07-19 Improvement in kettle for melting, mixing, and casting metals
DE296916C (OSRAM)
DE286431C (OSRAM)
US710223A (en) * 1901-06-10 1902-09-30 Thew Automatic Shovel Company Power-shovel.
SU64699A1 (ru) 1944-01-26 1944-11-30 А.И. Лютенберг Способ получени сол нокислого дигидрооксикодеинона
ES212554A1 (es) 1953-12-01 1954-08-16 Casanovas Albajes Cesar Un procedimiento para la obtención de un vidrio orgánico
US2772270A (en) 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US3173878A (en) * 1960-02-26 1965-03-16 Ibm Process of making microcapsules
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (OSRAM) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3916898A (en) 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
NL6714885A (OSRAM) 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3905981A (en) 1973-10-12 1975-09-16 Research Corp N-dealkylation of tertiary amines
US3894026A (en) 1973-10-16 1975-07-08 Merck & Co Inc Production of thebaine
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US3984026A (en) * 1976-03-26 1976-10-05 Shoup Russel W Combined can opening and sealing device
US4045440A (en) 1976-09-16 1977-08-30 The United States Of America As Represented By The Department Of Health, Education And Welfare Method of producing thebaine from codeine and oripavine from morphine
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4272540A (en) 1979-04-24 1981-06-09 Sisa, Incorporated 14-Methoxymorphinan-6-one compounds and therapeutic methods of treating pain and drug dependence with them
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4795813A (en) 1981-08-17 1989-01-03 The Florida Board Of Regents On Behalf Of The Florida State University Synthesis of derivatives of codeine and other 3-O-alkylmorphines
US5112975A (en) 1984-03-27 1992-05-12 Mallinckrodt Specialty Chemicals Company Preparation of noroxymorphone from morphine
US4639520A (en) 1984-03-27 1987-01-27 Mallinckrodt, Inc. Preparation of 14-hydroxy-N-ethoxy-carbonyl-norcodeinone
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4810699A (en) 1987-02-20 1989-03-07 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
US4810669A (en) * 1987-07-07 1989-03-07 Oki Electric Industry Co., Ltd. Method of fabricating a semiconductor device
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
HU208633B (en) 1991-02-04 1993-12-28 Alkaloida Vegyeszeti Gyar Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
JP3433871B2 (ja) * 1996-01-26 2003-08-04 株式会社デンソー 集積化半導体歪みセンサ及びその製造方法
PT1014941E (pt) 1996-06-26 2009-07-08 Univ Texas Formulação farmacêutica extrudível por termofusão
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
ES2121554B1 (es) * 1996-12-23 1999-06-16 Univ Santiago Compostela Procedimiento de obtencion de 14-hidroximofinonas mediante fotooxidac ion de alcaloides morfinicos con sistema alcoxidienico en el anillo c.
GB9713703D0 (en) 1997-06-30 1997-09-03 Johnson Matthey Plc Preparation of opiates
GB9717629D0 (en) 1997-08-21 1997-10-22 Johnson Matthey Plc Removal of residual organic solvents
US6710223B1 (en) 1997-09-10 2004-03-23 The Procter & Gamble Company Method for improving skin condition
GB9805516D0 (en) 1998-03-17 1998-05-13 Johnson Matthey Plc Preparation of opiates
EP1121234B1 (en) * 1998-10-14 2003-10-01 Gyros AB A matrix and method of producing said matrix
US6177567B1 (en) 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
US6284769B1 (en) * 1999-12-03 2001-09-04 The Board Of Trustees Of The University Of Illinois Nonpeptide kappa opioid receptor antagonists
US6133132A (en) * 2000-01-20 2000-10-17 Advanced Micro Devices, Inc. Method for controlling transistor spacer width
EA004876B1 (ru) * 2000-02-08 2004-08-26 Эро-Селтик, С.А. Устойчивые к порче композиции опиоидных агонистов для перорального введения
WO2001092188A1 (en) 2000-05-29 2001-12-06 Shionogi & Co., Ltd. Method for labeling with tritium
US7200357B2 (en) * 2000-10-20 2007-04-03 Universal Electronics Inc. Automotive storage and playback device and method for using the same
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
IL158882A0 (en) * 2001-06-05 2004-05-12 Control Delivery Sys Inc Sustained-release analgesic compounds
WO2002100382A2 (en) 2001-06-08 2002-12-19 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
SI1416842T1 (sl) 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
JP4669224B2 (ja) * 2002-01-15 2011-04-13 エアロジェン，インコーポレイテッド 有効解剖学的死腔からのエアロゾルを浄化するためのシステムおよび方法
SI1578350T1 (sl) * 2002-03-26 2009-10-31 Euro Celtique Sa Z gelom obloženi sestavki z zadržanim sproščanjem
NZ536252A (en) 2002-04-29 2007-06-29 Alza Corp Methods and dosage forms for controlled delivery of oxycodone
US7702280B2 (en) * 2002-05-27 2010-04-20 Ntt Docomo, Inc. Mobile communication system, transmission station, reception station, relay station, communication path deciding method, and communication path deciding program
CA2487786A1 (en) 2002-05-31 2003-12-11 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
CA2491572C (en) * 2002-07-05 2010-03-23 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
WO2004016618A1 (en) * 2002-08-15 2004-02-26 Noramco, Inc. Oxycodone-hydrochloride polymorhs
WO2004045551A2 (en) 2002-11-15 2004-06-03 Branded Products For The Future Pharmaceutical composition
AU2003293180A1 (en) * 2002-11-29 2004-06-23 Forest Laboratories Inc Combination of ibuprofen and oxycodone for acute pain relief
FR2850576B1 (fr) * 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
EP1603597B1 (en) 2003-03-13 2010-01-06 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
US6864370B1 (en) * 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070172958A1 (en) * 2004-03-30 2007-07-26 Euro-Celtique S.A. Methods for detecting 14-hydroxy codeinone and codeinone
TWI483944B (zh) * 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
US20050226929A1 (en) 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
JP5329083B2 (ja) 2004-06-25 2013-10-30 テッセラ，インコーポレイテッド ポストおよびパッドを有する部品
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
RS51131B (sr) 2005-03-04 2010-10-31 Euro-Celtique S.A. Postupak smanjenja alfa, beta nezasićenih ketona u opioidnim kompozicijama
ATE493417T1 (de) 2005-06-16 2011-01-15 Mallinckrodt Inc Synthetische route zu 14-hydroxylopiaten über 1- halogenthebain oder analoga
EP2402346A1 (en) 2005-11-22 2012-01-04 Controlled Chemicals, Inc. Processes for reducing contaminating Michael acceptor levels in oxycodone and other compositions
US20070117826A1 (en) 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
US8871779B2 (en) 2006-03-02 2014-10-28 Mallinckrodt Llc Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
CA2671518C (en) * 2006-12-04 2016-06-07 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
US7875719B2 (en) 2006-12-04 2011-01-25 Cox D Phillip Process for reducing impurities in oxycodone base
GB2450691A (en) 2007-07-02 2009-01-07 Alpharma Aps One-pot preparation of oxycodone from thebaine
PL2588481T3 (pl) 2010-07-02 2018-05-30 Johnson Matthey Public Limited Company Sposób syntezy i oczyszczania oksykodonu
US9062062B1 (en) * 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride

Also Published As

Publication number Publication date
DK1730151T3 (da) 2011-06-20
KR20100069719A (ko) 2010-06-24
US20160175300A1 (en) 2016-06-23
HK1155728A1 (en) 2012-05-25
HRP20110425T4 (hr) 2020-11-27
US20160185789A1 (en) 2016-06-30
CA2774121C (en) 2016-02-16
JP2007531756A (ja) 2007-11-08
CR8593A (es) 2007-07-19
EP1730151B2 (en) 2020-09-16
ME02411B (me) 2016-09-20
US9777011B2 (en) 2017-10-03
CY1117841T1 (el) 2017-05-17
NO20064935L (no) 2006-12-18
MA28492B1 (fr) 2007-03-01
US10259819B2 (en) 2019-04-16
CN102838607A (zh) 2012-12-26
IL235298A (en) 2016-11-30
EP2305683B2 (en) 2024-09-11
MY172063A (en) 2019-11-13
PL1730151T3 (pl) 2011-08-31
US9073933B2 (en) 2015-07-07
EP2316837B1 (en) 2018-01-10
KR20130020962A (ko) 2013-03-04
US20210198268A1 (en) 2021-07-01
ES2585576T3 (es) 2016-10-06
EP1730151B1 (en) 2011-03-09
EP2319846A1 (en) 2011-05-11
RS54598B1 (sr) 2016-08-31
AU2009200335A1 (en) 2009-02-26
CA2557845A1 (en) 2005-10-20
ECSP066953A (es) 2006-12-20
US9522919B2 (en) 2016-12-20
ATE501150T1 (de) 2011-03-15
PL2426132T3 (pl) 2016-06-30
US12060361B2 (en) 2024-08-13
AT9952U1 (de) 2008-06-15
NO337669B1 (no) 2016-05-30
PT2319846T (pt) 2016-08-12
CA2557845C (en) 2013-10-01
SI2319846T1 (sl) 2016-08-31
DK200700214U1 (da) 2007-11-23
JP6503392B2 (ja) 2019-04-17
US20130005977A1 (en) 2013-01-03
EP2311839A1 (en) 2011-04-20
IL214050A (en) 2013-09-30
NZ602862A (en) 2014-01-31
US11236098B2 (en) 2022-02-01
US20160185788A1 (en) 2016-06-30
KR20090104145A (ko) 2009-10-05
RS53891B1 (sr) 2015-08-31
MX2020008878A (es) 2020-11-09
KR20070022033A (ko) 2007-02-23
EP2319846B1 (en) 2016-05-04
KR20200000499A (ko) 2020-01-02
CN101812065B (zh) 2012-03-28
US7674800B2 (en) 2010-03-09
JP5118223B2 (ja) 2013-01-16
US7674799B2 (en) 2010-03-09
ES2566363T3 (es) 2016-04-12
HRP20150358T1 (hr) 2015-05-08
CY1116327T1 (el) 2017-02-08
RS51693B2 (sr) 2021-02-26
EP2305683A1 (en) 2011-04-06
ME03068B (me) 2019-01-20
PL2305683T3 (pl) 2015-07-31
US7683072B2 (en) 2010-03-23
EP2314589B1 (en) 2022-12-28
LT2316837T (lt) 2018-04-10
EP1730151A4 (en) 2007-05-23
PT2305683E (pt) 2015-05-18
HK1098745A1 (en) 2007-07-27
DK200700214U3 (da) 2008-02-08
JP2018184462A (ja) 2018-11-22
IL213890A (en) 2015-10-29
IL214050A0 (en) 2011-08-31
US10689389B2 (en) 2020-06-23
WO2005097801A1 (en) 2005-10-20
RS54941B1 (sr) 2016-11-30
IL213891A0 (en) 2011-07-31
US20150265598A1 (en) 2015-09-24
IL178038A0 (en) 2006-12-31
PT1730151E (pt) 2011-06-01
US20070117829A1 (en) 2007-05-24
SG170736A1 (en) 2011-05-30
US20070117831A1 (en) 2007-05-24
JP5543991B2 (ja) 2014-07-09
CN102887903A (zh) 2013-01-23
TW200540177A (en) 2005-12-16
US20160250205A1 (en) 2016-09-01
HRP20160885T1 (hr) 2016-09-23
IL241117B (en) 2020-06-30
IL213890A0 (en) 2011-07-31
AR049012A1 (es) 2006-06-21
HK1155729A1 (en) 2012-05-25
US20150265597A1 (en) 2015-09-24
CN102127086A (zh) 2011-07-20
ES2535618T3 (es) 2015-05-13
TWI365880B (en) 2012-06-11
US20090227615A1 (en) 2009-09-10
JP5378486B2 (ja) 2013-12-25
KR20150046393A (ko) 2015-04-29
US20070117830A1 (en) 2007-05-24
US11384091B2 (en) 2022-07-12
TW201509943A (zh) 2015-03-16
CN1960994B (zh) 2012-09-05
AP2232A (en) 2011-05-04
CN102127086B (zh) 2013-11-27
PT2426132E (pt) 2016-03-31
US20210094963A1 (en) 2021-04-01
EP2426132A1 (en) 2012-03-07
IL178038A (en) 2015-10-29
IL213888A0 (en) 2011-07-31
HRP20110425T1 (en) 2011-07-31
US20200087316A1 (en) 2020-03-19
IL241117A0 (en) 2015-11-30
FIU20070284U0 (fi) 2007-07-04
AU2005230826C1 (en) 2014-10-16
AU2005230826B2 (en) 2008-11-06
RS51693B (sr) 2011-10-31
KR100930730B1 (ko) 2009-12-09
US20190161492A1 (en) 2019-05-30
US20160250204A1 (en) 2016-09-01
EA200601520A1 (ru) 2007-02-27
KR20140133615A (ko) 2014-11-19
DE602005026786D1 (de) 2011-04-21
KR20110110377A (ko) 2011-10-06
SI1730151T1 (sl) 2011-06-30
CA2774121A1 (en) 2005-10-20
CN101812065A (zh) 2010-08-25
ZA200607181B (en) 2007-11-28
US20100152449A1 (en) 2010-06-17
CN1960994A (zh) 2007-05-09
US20160176889A1 (en) 2016-06-23
US8822687B2 (en) 2014-09-02
TWI483944B (zh) 2015-05-11
MY143205A (en) 2011-03-31
DK1730151T4 (da) 2020-10-19
KR20140021716A (ko) 2014-02-20
US20230159548A1 (en) 2023-05-25
KR20180088505A (ko) 2018-08-03
US20160251364A1 (en) 2016-09-01
JP2015187134A (ja) 2015-10-29
EP2314589A1 (en) 2011-04-27
ME01299B (me) 2011-10-31
EP1730151A1 (en) 2006-12-13
ES2938727T3 (es) 2023-04-14
CA2913355A1 (en) 2005-10-20
JP4912294B2 (ja) 2012-04-11
DK2305683T3 (en) 2015-04-07
DK2426132T3 (en) 2016-04-04
US20230365578A1 (en) 2023-11-16
TW201231469A (en) 2012-08-01
US20070179169A1 (en) 2007-08-02
US20160251365A1 (en) 2016-09-01
CR20110376A (es) 2011-09-19
KR101200700B1 (ko) 2012-11-13
CA2913355C (en) 2021-04-20
CN102838607B (zh) 2016-08-03
SI2305683T1 (sl) 2015-04-30
EA013208B1 (ru) 2010-04-30
JP2012188439A (ja) 2012-10-04
HUE029913T2 (en) 2017-04-28
ES2665287T3 (es) 2018-04-25
PL2319846T3 (pl) 2016-12-30
US20150258086A1 (en) 2015-09-17
US20160251363A1 (en) 2016-09-01
US10407434B2 (en) 2019-09-10
JP2012072162A (ja) 2012-04-12
HUE036451T2 (hu) 2018-07-30
EP2316837A1 (en) 2011-05-04
PL2316837T3 (pl) 2018-07-31
JP2017125052A (ja) 2017-07-20
US20160175299A1 (en) 2016-06-23
US20160175298A1 (en) 2016-06-23
AU2009200335B2 (en) 2011-07-28
JP2011157370A (ja) 2011-08-18
DK2316837T3 (en) 2018-04-16
BRPI0508758A (pt) 2007-08-28
NZ601326A (en) 2013-10-25
PT2316837T (pt) 2018-04-02
SI1730151T2 (sl) 2021-03-31
HUE028233T2 (en) 2016-12-28
HRP20180407T1 (hr) 2018-04-20
AU2005230826A1 (en) 2005-10-20
NZ549430A (en) 2010-05-28
IL213889A0 (en) 2011-07-31
MY154985A (en) 2015-08-28
MX363228B (es) 2019-03-15
BRPI0508758B8 (pt) 2021-05-25
US7674798B2 (en) 2010-03-09
DE202005021371U1 (de) 2007-10-25
US20060173029A1 (en) 2006-08-03
KR20120106784A (ko) 2012-09-26
CY1120171T1 (el) 2018-12-12
SI2316837T1 (en) 2018-05-31
US20050222188A1 (en) 2005-10-06
CN102887903B (zh) 2016-01-27
FI7843U1 (fi) 2008-04-28
US20200062772A1 (en) 2020-02-27
AP2006003738A0 (en) 2006-10-31
BRPI0508758B1 (pt) 2018-10-09
US20160264588A1 (en) 2016-09-15
RS57000B1 (sr) 2018-05-31
KR101410141B1 (ko) 2014-06-25
PE20050880A1 (es) 2005-11-16
ME02482B (me) 2017-02-20
SG170735A1 (en) 2011-05-30
US20160176888A1 (en) 2016-06-23
SG10201406658VA (en) 2014-12-30
KR20120046309A (ko) 2012-05-09
DK2319846T3 (en) 2016-08-15
ES2362282T5 (es) 2021-06-24
PL1730151T5 (pl) 2023-09-18
US10696684B2 (en) 2020-06-30
JP2014139205A (ja) 2014-07-31
EP2305683B1 (en) 2015-01-28
EP2305683B8 (en) 2015-03-04
CY1117228T1 (el) 2017-04-05
HRP20160223T1 (hr) 2016-03-25
KR100993911B1 (ko) 2010-11-11
US20180022754A1 (en) 2018-01-25
US7129248B2 (en) 2006-10-31
US20160185790A1 (en) 2016-06-30
IL213889A (en) 2012-06-28
SI2426132T1 (sl) 2016-04-29
ES2362282T3 (es) 2011-06-30
CY1111487T1 (el) 2015-08-05
EP2426132B1 (en) 2016-01-13
US20110207762A1 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
PL2426132T3 (pl) Spusób wytwarzania kompozycji chlorowodorku oksykodonu zawierającej mniej niż 25 ppm 14-hydroksykodeinonu
IL197402A0 (en) Process for preparing n-alkyl naltrexone halides
ZA200708537B (en) Process for preparing nutritional compositions
EP1751123A4 (en) PROCESS FOR PREPARING IRBESARTAN
ZA200701532B (en) Process for making tea
IL182211A0 (en) Process for preparing purine compounds
GB0416694D0 (en) Process for preparing microcrystals
ZA200703495B (en) Process for the preparation of irbesartan hydrochloride
ZA200701867B (en) Process for making tea
IL178069A0 (en) Process for preparing n-aryl-piperazine derivatives
IL179994A0 (en) Improved process for preparing imiquimod
IL183804A0 (en) Process for preparing substituted 2-alkoxycarbonyl-3-aminothiophenes
GEP20094655B (en) Process for preparing oxycodone hydrochloride having less than 25 pm 14-hydroxycodeinone
GB0409133D0 (en) Methods for preparing pharmaceutical compositions
GB0407724D0 (en) Process for preparing bicyclic compounds
GB0408249D0 (en) Improved process for tea manufacture
ZA200607802B (en) Process for preparing N-aryl-piperazine derivatives